10-Q: Moderna Q2 2026 Earnings: Revenue Up, Net Loss Widens

Moderna reported Q2 2026 results with total revenue increasing to $145 million, driven by other revenue, while net loss slightly narrowed to $782 million.

Summary

• Total revenue for the second quarter of 2026 was $145 million, a slight increase from $142 million in the second quarter of 2025.
• Net product sales decreased by 18% to $94 million in Q2 2026, primarily due to lower COVID vaccine sales in the US and South America.
• Other revenue increased by 82% to $51 million in Q2 2026, driven by stand-ready manufacturing and collaboration revenue.
• For the first six months of 2026, total revenue significantly increased by 114% to $534 million, with net product sales up 123% to $446 million.
• Cost of sales for Q2 2026 was $93 million, a decrease of 22% from Q2 2025, but increased significantly for the six-month period to $1.0 billion due to litigation settlement expenses.
• Research and development expenses decreased by 7% to $651 million in Q2 2026, and by 16% to $1.3 billion for the six-month period.
• Selling, general and administrative expenses decreased by 6% to $216 million in Q2 2026, and by 12% to $389 million for the six-month period.
• Net loss for Q2 2026 was $782 million, a slight improvement from $825 million in Q2 2025. Net loss for the six months ended June 30, 2026, was $2.125 billion, an increase from $1.796 billion in the prior year period.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative sentiment, with revenue growth offset by a widening net loss and significant legal liabilities, though positive developments in new product approvals and pipeline progress provide some optimism.

Positives

• Total revenue increased by 2% to $145 million in Q2 2026 compared to Q2 2025.
• Total revenue for the first six months of 2026 increased by 114% to $534 million compared to the same period in 2025.
• Net product sales for the first six months of 2026 increased by 123% to $446 million, primarily due to higher COVID vaccine sales in international markets.
• Other revenue increased by 82% to $51 million in Q2 2026, driven by stand-ready manufacturing and collaboration revenue.
• Research and development expenses decreased by 7% in Q2 2026 and 16% for the six-month period, reflecting portfolio reprioritization.
• Selling, general and administrative expenses decreased by 6% in Q2 2026 and 12% for the six-month period, reflecting cost discipline.
• European Commission marketing authorization received for mCOMBRIAX (mRNA-1083), a combination flu and COVID vaccine.
• FDA Advisory Committee provided a unanimous positive recommendation for mRNA-1010 (seasonal flu vaccine).

Negatives

• Net product sales decreased by 18% to $94 million in Q2 2026, primarily due to lower COVID vaccine sales in the United States and South America.
• Net loss for Q2 2026 was $782 million, compared to $825 million in Q2 2025.
• Net loss for the six months ended June 30, 2026, increased by 18% to $2.125 billion compared to the same period in 2025.
• Cost of sales for the six months ended June 30, 2026, increased by 401% to $1.0 billion, primarily driven by litigation settlement-related expenses.
• Cash, cash equivalents, and investments decreased by $1.2 billion to $6.9 billion as of June 30, 2026, compared to December 31, 2025.
• Working capital decreased by 28% to $3.3 billion as of June 30, 2026, compared to December 31, 2025.
• The company recorded $950 million in accrued liabilities for a litigation settlement with Arbutus and Genevant.
• The company is appealing a District Court decision related to 28 U.S.C. § 1498, which could result in an additional payment of up to $1.3 billion.

Risks

• The outcome of patent-infringement actions against Pfizer, BioNTech, GSK, Northwestern University, Bayer CropSciences, mNG Bio, CureVac, and Sanofi subsidiaries is uncertain.
• The company is subject to shareholder class action and derivative litigation related to statements about its RSV vaccine (mRNA-1345).
• A settlement with Arbutus and Genevant included a $950 million payment and an ongoing appeal that could result in an additional payment of up to $1.3 billion.
• The market for COVID vaccines is transitioning to a more competitive and commercially driven environment, impacting demand.
• The company may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors that could adversely affect its business.
• Continued investment in future product launches may lead to continued negative cash flows from operations.
• The company's forecast of the period of time its financial resources will be adequate is based on assumptions that may prove to be wrong.
• The company faces risks related to the development and commercialization of novel medicines, including potential regulatory hurdles and market acceptance.

Future Outlook

Product sales are expected to return to growth in 2026, supported by long-term strategic partnerships with government entities. A modest decrease in cost of sales is anticipated for 2026 compared to 2025, excluding the impact of the Arbutus/Genevant settlement. Research and development expenses are expected to see a modest reduction in 2026 compared to 2025, driven by program wind-downs and cost management. Selling, general and administrative expenses are expected to remain relatively consistent with 2025 levels.

Management Comments

• We are advancing a new class of medicines made of messenger RNA (mRNA).
• We have transformed from a research-stage company to a commercial enterprise with a diverse clinical portfolio.
• We received marketing authorization from the European Commission for mCOMBRIAX.
• The FDA's Vaccines and Related Biological Products Advisory Committee voted unanimously that the benefits of mRNA-1010 outweigh its risks.
• We expanded our strategic collaboration with CEPI to advance the development of a potential vaccine against Bundibugyo ebolavirus (BDBV).
• We anticipate a modest decrease in research and development expenses in 2026 compared to 2025.
• We expect selling, general and administrative expenses in 2026 to remain at a level relatively consistent with 2025.
• We believe that our cash, cash equivalents, and investments, together with available borrowings, will be sufficient to fund our projected operations and capital expenditures through at least the next 12 months.

Industry Context

StockSavvy.ai notes that Moderna's Q2 2026 results reflect the ongoing transition in the COVID-19 vaccine market towards a more commercial landscape, impacting product sales. The company's strategic focus on expanding its respiratory vaccine portfolio with approvals like mCOMBRIAX and advancing its oncology and rare disease pipelines are key differentiators in the competitive biotechnology sector.

Comparison to Industry Standards

• Moderna's net loss of $782 million for Q2 2026, while significant, is a slight improvement from the prior year's $825 million, indicating a potential stabilization in operational losses.
• The substantial increase in revenue for the first six months of 2026 ($534 million vs. $250 million in 2025) highlights the company's ability to scale revenue generation, particularly from international markets and new product launches, which is a positive sign compared to many early-stage biotech firms.
• The significant increase in cost of sales for the six-month period (401%) is heavily influenced by a one-time litigation settlement, making direct comparison to industry cost-of-goods-sold ratios challenging without this adjustment. Excluding this, cost of sales as a percentage of revenue would show improvement.
• The company's R&D spending reduction of 16% for the first six months of 2026, while indicative of cost management, needs to be monitored to ensure it does not impede future pipeline development compared to peers who may be increasing R&D investment in key therapeutic areas.

Legal Proceedings

• Patent-infringement actions against Pfizer Inc., BioNTech SE, GlaxoSmithKline Biologicals SA, Northwestern University, Bayer CropSciences LLC, Monsanto Company, Monsanto Technology, LLC, mNG Bio, LLC, CureVac SE, CureVac Manufacturing GmbH, Translate Bio, Inc., Translate Bio MA, Inc., Sanofi Vaccines US, Inc., and VaxServe, Inc.
• Shareholder class action and shareholder derivative litigation related to statements about the RSV vaccine (mRNA-1345).
• Settlement agreement with Arbutus Biopharma Corporation and Genevant Sciences GmbH resolving all worldwide litigation, with a $950 million payment and an ongoing appeal that could result in an additional payment of up to $1.3 billion.

Stakeholder Impact

• Shareholders: The net loss and significant legal liabilities may impact share price and investor confidence, while pipeline progress and new product approvals offer potential upside.
• Employees: Continued R&D investment and commercialization efforts may lead to job creation and growth opportunities, balanced by cost management initiatives.
• Customers: Availability of new vaccines like mCOMBRIAX and continued supply of existing vaccines are critical for public health.
• Suppliers: Ongoing manufacturing and R&D activities will continue to drive demand for raw materials and services.
• Creditors: The company's liquidity and debt levels, including the credit facility, will be monitored.

Next Steps

• Commercialize mCOMBRIAX across the EU, subject to national regulatory and access procedures.
• Await further guidance from the FDA on refiling the submission for the flu plus COVID combination vaccine.
• Continue advancing mRNA-4157 in collaboration with Merck across multiple tumor types.
• Expect potential Phase 3 adjuvant melanoma data in 2026 for mRNA-4157.
• Expect potential data in 2026 for the propionic acidemia (PA) therapeutic (mRNA-3927).
• Continue to manage research and development investment levels in line with long-term objectives.
• Continue selective investments to support global commercial and regulatory activities, offset by efficiency initiatives.
• Monitor the outcome of the appeal related to the Arbutus/Genevant settlement.

Key Dates

Recommendation

Moderna's Q2 2026 report shows revenue growth driven by new products and international sales, which is positive. However, the significant net loss, substantial accrued liabilities from litigation, and the ongoing appeal introduce considerable risk. While the pipeline and regulatory progress are encouraging, the financial performance and legal uncertainties warrant a cautious 'hold' stance until a clearer path to sustained profitability and resolution of legal matters emerges.

Keywords

mRNA vaccines, COVID-19 vaccine, RSV vaccine, flu vaccine, oncology therapeutics, rare disease therapeutics, clinical trials, regulatory approval